Jagsonpal Pharmaceuticals Limited · JAGSNPHARM
Every Jagsonpal Pharmaceuticals Limited result whose ten-session window has closed, judged against the last read made before it. Open a result for the full account: the read, the sessions after, the reported figures, and every morning's read that led up to it. The company's own page →
25results judged
1read right
2read wrong
3flat / no call
19unread
56%beat the market
+4.8%avg vs market, 10d
4.4%avg move, T+1
How the reads on it fared
| Read | Judged | Right | Wrong | Flat | Hit rate | Avg vs mkt | |
|---|---|---|---|---|---|---|---|
| strong | 4 | 1 | 2 | 1 | 33% | -3.6% | |
| neutral | 1 | 0 | 0 | 1 | — | -8.7% | |
| unfavourable | 1 | 0 | 0 | 1 | — | +0.1% | |
| unread | 19 | 0 | 0 | 0 | — | +7.6% |
A company that is often read strong and often proves it is one the model understands; one that is read strong and keeps lagging is where the model is wrong about a name, and this table is where that shows first.
Reading the rows
- T+1
- the share's move on the first session after the result, from the close before it
- T+10
- the move over ten sessions, same base
- vs market
- T+10 less NIFTY 50's move over the same ten sessions — the number every read is judged on
- Run-up
- the share's move in the thirty sessions before the result
- Result
- reported profit growth against the company's own last four quarters: good, in line, bad
Each result
25 judged · newest first · open one| Result | Read | Outcome | T+1 | T+10 | vs market | Run-up | Result | Why | |
|---|---|---|---|---|---|---|---|---|---|
| 29 Jul Q1FY27 | strong | neutral | +0.1% | -0.2% | -0.8% | +10% | no figures |
|
› |
| 27 Apr Q4FY26 | strong | right | +2.5% | +3.0% | +5.8% | +7% | no figures |
|
› |
| 21 Jan Q3FY26 | unfavourable | neutral | -0.4% | +2.3% | +0.1% | -19% | no figures |
|
› |
| 3 Nov Q2FY26 | neutral | neutral | -4.3% | -7.6% | -8.7% | -7% | no figures |
|
› |
| 26 Jul Q1FY26 | strong | wrong | +9.8% | -5.2% | -4.2% | +13% | no figures |
|
› |
| 6 May Q4FY25 | strong | wrong | -12.5% | -13.3% | -15.1% | +11% | no figures |
|
› |
| 23 Jan Q3FY25 | — | unread | -16.3% | +4.6% | +3.1% | -6% | no figures |
|
› |
| 24 Oct Q2FY25 | — | unread | -4.7% | +26.4% | +27.4% | +14% | no figures |
|
› |
| 8 Aug Q1FY25 | — | unread | +3.0% | +12.2% | +8.5% | +8% | no figures |
|
› |
| 21 May Q4FY24 | — | unread | -3.9% | -16.0% | -13.4% | +19% | no figures |
|
› |
| 2 Feb Q3FY24 | — | unread | -18.2% | -12.5% | -13.7% | -3% | no figures |
|
› |
| 3 Aug Q1FY24 | — | unread | -6.0% | -2.5% | -2.5% | +24% | no figures |
|
› |
| 24 May Q4FY23 | — | unread | -1.2% | +5.0% | +3.6% | +8% | no figures |
|
› |
| 10 Feb Q3FY23 | — | unread | -1.2% | -3.0% | -0.4% | -10% | no figures |
|
› |
| 10 Nov Q2FY23 | — | unread | +0.1% | -10.3% | -12.9% | -7% | no figures |
|
› |
| 10 Aug Q1FY23 | — | unread | +9.1% | +9.9% | +9.7% | +13% | no figures |
|
› |
| 31 May Q4FY22 | — | unread | +1.9% | +1.0% | +6.4% | -11% | no figures |
|
› |
| 13 Feb Q3FY22 | — | unread | -0.9% | +44.6% | +47.9% | -7% | no figures |
|
› |
| 21 Oct Q2FY22 | — | unread | -0.4% | +8.4% | +9.0% | +13% | no figures |
|
› |
| 14 Aug Q1FY22 | — | unread | -5.1% | -15.7% | -19.4% | +17% | no figures |
|
› |
| 2 Jul Q4FY21 | — | unread | -2.2% | +12.4% | +12.2% | +55% | no figures |
|
› |
| 12 Feb Q3FY21 | — | unread | +0.1% | +13.3% | +17.5% | +15% | no figures |
|
› |
| 11 Nov Q2FY21 | — | unread | +2.0% | +58.1% | +56.2% | +7% | no figures |
|
› |
| 30 Jul Q4FY20 | — | unread | -2.1% | +3.1% | +2.3% | +12% | no figures |
|
› |
| 30 Jul Q1FY21 | — | unread | -2.1% | +3.1% | +2.3% | +12% | no figures |
|
› |